Upping the antedrug: Is a novel anti-inflammatory Toll-like receptor 7 agonist also a bronchodilator?

E. H. Kaufman, D. B. Jacoby

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


In this issue of British Journal of Pharmacology, Biffen and colleagues present a novel Toll-like receptor 7 (TLR7) antedrug to treat allergic disease that is rapidly metabolized in the lung to limit side effects due to systemic exposure. Asthma is characterized as an allergic disease of the lung, and TLR7 agonists are proposed to ameliorate allergic inflammation in the lung, a characteristic of prophylactic medications. We have previously shown that TLR7 agonists of multiple structural classes are acute bronchodilators, characteristic of rescue medication for asthma attacks. It will be interesting to determine whether the bronchodilating effect extends to the novel class of TLR7 agonists described here for a prophylactic and rescue therapy in one drug. Combined with the antedrug approach, this would further limit side effects improving on current combination therapies.

Original languageEnglish (US)
Pages (from-to)569-572
Number of pages4
JournalBritish Journal of Pharmacology
Issue number2
StatePublished - May 2012


  • Toll-like receptor 7
  • allergy
  • antedrug
  • asthma
  • bronchodilator
  • immunomodulator
  • inflammation

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Upping the antedrug: Is a novel anti-inflammatory Toll-like receptor 7 agonist also a bronchodilator?'. Together they form a unique fingerprint.

Cite this